美康生物科技股份有限公司 为保障公司董事会审计委员会的正常运行，根据《公司法》《公司章程》、 公司《董事会专门委员会工作制度》等法律法规、规范性文件的有关规定，公司 董事会补选职工代表董事黄盖鹏先生为公司第五届董事会审计委员会委员，与徐 玲女士（委员会召集人）、田云鹏先生共同组成第五届董事会审计委员会，任期 自本次董事会会议审议通过之日起至第五届董事会届满之日止。 具体内容详见同日刊登在中国证券监督管理委员会指定的创业板信息披露 网站上的相关公告。 第五届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 美康生物科技股份有限公司（以下简称"公司"）第五届董事会第十七次会 议于 2025 年 11 月 14 日在公司会议室以现场表决的方式召开，经全体董事同意 豁免本次会议通知期限要求，于 2025 年 11 月 14 日通过电话和口头的方式送达 全体董事。会议应出席董事 5 人，实际出席董事 5 人，会议由董事长邹炳德先生 召集并主持。本次会议的召集、召开符合《中华人民共和国公司法》（以下简称 "《公司法》"）、《美康生物科技股份有限公 ...

Group 1: Establishment of the Joint Laboratory - The signing ceremony for the establishment of the Cardiovascular Metabolism Precision Diagnosis Collaborative Innovation Joint Laboratory between Peking University First Hospital and Meikang Bio was held in Beijing [1] - The laboratory will focus on lipoprotein profiling research to identify more precise intervention targets, aiming for breakthroughs in chronic disease prevention and treatment [1][2] - The collaboration is expected to enhance personalized medical development and provide more accurate treatment plans for patients [1][3] Group 2: Importance of VAP Technology - VAP (Vertical Auto Profile) technology is highlighted as an advanced method for analyzing lipoprotein subcomponents, which is crucial for assessing cardiovascular disease risk [2][4] - The technology allows for comprehensive and precise evaluation of atherosclerotic cardiovascular disease risks and supports the efficacy evaluation of lipid-lowering medications [2][4] - VAP technology has been recognized in multiple authoritative guidelines, indicating its significance in clinical applications [5] Group 3: Meikang Bio's Role and Achievements - Meikang Bio, established in 2003, is a leading enterprise in the in vitro diagnostic industry in China, focusing on the development, production, and sales of diagnostic instruments and reagents [6] - The company has obtained numerous product registrations, including 497 for in vitro diagnostic reagents and 50 for diagnostic instruments, showcasing its extensive product line [6] - Meikang Bio aims to integrate research, production, and clinical application to enhance its competitive edge in the market [6] Group 4: Future Directions and Goals - The joint laboratory aims to build a high-level team and undertake major national projects to continuously optimize VAP technology and improve detection capabilities [3][9] - The collaboration is positioned as a significant step towards addressing residual cardiovascular risks and contributing to the "Healthy China" initiative [3][9] - Meikang Bio plans to enhance its detection and service capabilities by leveraging its advanced technology platforms to meet the growing demand for disease diagnosis and health management in China [9]

Core Viewpoint - Meikang Bio (300439.SZ) has received a medical device registration certificate for its Heparin-Binding Protein Test Kit, enhancing its product line in the in vitro diagnostic sector and positively impacting future operations [1] Group 1 - Meikang Bio's subsidiary, Jiangxi Meikang Shengde Biotechnology Co., Ltd., obtained the registration certificate from the Jiangxi Provincial Drug Administration [1] - The product, Heparin-Binding Protein Test Kit, utilizes chemiluminescent immunoassay technology [1] - The acquisition of this certificate enriches the company's offerings in the in vitro diagnostic field, improving its core competitiveness and market expansion capabilities [1]

Core Viewpoint - Meikang Bio (300439.SZ) announced that its subsidiary, Jiangxi Meikang Shengde Biotechnology Co., Ltd., has obtained the Medical Device Registration Certificate for in vitro diagnostic reagents from the Jiangxi Provincial Drug Administration, enhancing its product line in the field of chemiluminescence immunoassay [1] Group 1 - The newly acquired registration certificate pertains to the "Heparin-Binding Protein Detection Kit (Chemiluminescence Immunoassay Method)" [1] - This achievement enriches the company's product offerings in the niche market of in vitro diagnostic chemiluminescence [1] - The development is expected to enhance the company's core competitiveness and market expansion capabilities, positively impacting future operations [1]

Group 1 - The core point of the article is that Meikang Bio (SZ 300439) announced that its subsidiary, Jiangxi Meikang Shengde Biotechnology Co., Ltd., has obtained a medical device registration certificate for the "Heparin Binding Protein Test Kit" from the Jiangxi Provincial Drug Administration [1] - For the year 2024, Meikang Bio's revenue composition is expected to be 100% from medical devices [1] - As of the time of reporting, Meikang Bio has a market capitalization of 4.1 billion yuan [1] Group 2 - The article also mentions that prior to the arrest of Xu Xiren, the chairman of Peking University Medicine, the police had investigated the group's factory premises [1] - Internal sources indicate that the group's assets have been disposed of by Xu, with a significant amount of funds unaccounted for [1]

Core Viewpoint - Meikang Bio (300439.SZ) announced that its subsidiary, Jiangxi Meikang Shengde Biotechnology Co., Ltd., has obtained the Medical Device Registration Certificate for in vitro diagnostic reagents from the Jiangxi Provincial Drug Administration, specifically for the "Heparin-Binding Protein Test Kit (Chemiluminescent Immunoassay)" [1] Group 1 - The acquisition of the registration certificate enhances the product line in the niche market of in vitro diagnostic chemiluminescence [1] - This development is expected to strengthen the company's core competitiveness and market expansion capabilities [1] - The positive impact on the company's future operations is anticipated as a result of this certification [1]

一、医疗器械注册证的具体情况 | 序号 | 注册人名称 | 产品名称 | 注册证编号 | | | 注册证有效期间 | | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | 用于体外定量测定人血浆肝 | | 1 | 江西美康 | 肝素结合蛋白检测试剂盒 | 赣 械 | 注 | 准 | 年 月 2025 4 | 11 | 日至 | 素结合蛋白（HBP）的浓度。 | | | | （化学发光免疫分析法） | 20252400234 | | | 2030 年 月 | 11 | 3 日 | 临床上可作为炎症的辅助指 | | | | | | | | | | | 标。 | 二、对公司业绩的影响及风险提示 上述《注册证》的取得，丰富了公司在体外诊断化学发光细分领域产品线的 品种，有利于进一步提升公司的核心竞争力和市场拓展能力，对公司未来的经营 将产生积极影响。上述产品实际销售情况取决于未来市场推广效果，公司目前尚 无法预测其对公司未来业绩的影响，敬请投资者注意投资风险。 美康生物科技股份有限公司 ...

美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 公告编号：2025-068 美康生物科技股份有限公司 关于召开 2025 年第一次临时股东大会的提示性公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 美康生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召 开了第五届董事会第十六次会议，会议审议通过了《关于召开公司 2025 年第一 次临时股东大会的议案》，决定于 2025 年 11 月 14 日（星期五）召开公司 2025 年第一次临时股东大会，相关内容详见公司于 2025 年 10 月 29 日在巨潮资讯网 （www.cninfo.com.cn）上刊登的相关公告（公告编号：2025-065）。 本次股东大会将采取网络投票和现场投票相结合的方式召开，为保护投资者 合法权益，方便各位股东行使股东大会表决权，现将有关事项提示公告如下： 一、本次股东大会召开的基本情况 1、会议届次：2025 年第一次临时股东大会。 2、会议召集人：公司第五届董事会 3、会议召开的合法、合规性：经公司第五届董事会第十六次会议审议通过 ...

Core Viewpoint - Meikang Bio (300439) announced that its subsidiary, Jiangxi Meikang Shengde Biotechnology Co., Ltd., has obtained a medical device registration certificate for an in vitro diagnostic reagent, specifically a heparin-binding protein test kit, which can serve as an auxiliary indicator for inflammation [1] Group 1 - The product is named the heparin-binding protein test kit (chemiluminescent immunoassay) [1] - The test kit is designed for the quantitative measurement of heparin-binding protein (HBP) concentration in human plasma [1] - The clinical application of the product is as an auxiliary indicator for inflammation [1]

Core Viewpoint - Meikang Bio is a leading company in the in vitro diagnostic field in China, with strong market competitiveness and a diverse range of self-developed products [1] Group 1: Business Performance - In Q3 2025, Meikang Bio reported revenue of 1.136 billion yuan, ranking 8th out of 39 in the industry, surpassing the industry average of 708 million yuan and the median of 330 million yuan, but still significantly behind the top two competitors, New Industries at 3.428 billion yuan and Antu Bio at 3.127 billion yuan [2] - The net profit for the same period was 58.8936 million yuan, ranking 15th out of 39, above the industry median of 26.1892 million yuan but below the industry average of 110 million yuan, with a notable gap from the leaders, Ji'an Medical at 1.588 billion yuan and New Industries at 1.205 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Meikang Bio's debt-to-asset ratio was 19.34%, slightly higher than the previous year's 19.16% and above the industry average of 18.29% [3] - The gross profit margin for Q3 2025 was 39.64%, down from 45.80% in the previous year and below the industry average of 56.20% [3] Group 3: Executive Compensation - Chairman Zou Bingde's compensation for 2024 was 1.7668 million yuan, an increase of 566,800 yuan from 2023 [4] - General Manager Zou Jihua's compensation for 2024 was 869,900 yuan, an increase of 69,800 yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders for Meikang Bio decreased by 6.95% to 23,900, while the average number of circulating A-shares held per shareholder increased by 7.47% to 12,200 [5]